GSTP1, a novel downstream regulator of LRRK2, G2019S-induced neuronal cell death

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 7, 2012, Pages 2365-2377

  Chen, Jie ^a   Liou, Anthony ^b   Zhang, Lili ^b   Weng, Zhongfang ^b   Gao, Yanqin ^a   Cao, Guodong ^a,b,c   Zigmond, Michael J ^a,b   Chen, Jun ^a,b,c  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; GSTP1; LRRK2. G2019S; Parkinson

Indexed keywords

CASPASE 3; GLUTATHIONE TRANSFERASE P1; LEUCINE RICH REPEAT KINASE 2; SHORT HAIRPIN RNA; GLUTATHIONE TRANSFERASE; LRRK2 PROTEIN, HUMAN; PRIMER DNA; PROTEIN SERINE THREONINE KINASE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; PROMOTER REGION; PROTEIN EXPRESSION; PROTEOMICS; TRANSCRIPTION REGULATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; CELL DEATH; CYTOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NERVE CELL; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; REAL TIME POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE; WESTERN BLOTTING;

BASE SEQUENCE; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLUTATHIONE TRANSFERASE; HUMANS; NEURONS; PROTEIN-SERINE-THREONINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84867316285     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e548     Document Type: Article

References (38)

1. Bosgraaf, L. & P. J. Van Haastert: Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta, 1643, 5-10 (2003)) (Pubitemid 37494887)
2. Funayama, M., K. Hasegawa, H. Kowa, M. Saito, S. Tsuji & F. Obata: A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol, 51, 296-301 (2002)) (Pubitemid 34206285)
3. Deng, H., W. Le, Y. Guo, C. B. Hunter, W. Xie & J. Jankovic: Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol, 57, 933-4 (2005)) (Pubitemid 40798637)
4. Goldwurm, S., A. Di Fonzo, E. J. Simons, C. F. Rohe, M. Zini, M. Canesi, S. Tesei, A. Zecchinelli, A. Antonini, C. Mariani, N. Meucci, G. Sacilotto, F. Sironi, G. Salani, J. Ferreira, H. F. Chien, E. Fabrizio, N. Vanacore, A. Dalla Libera, F. Stocchi, C. Diroma, P. Lamberti, C. Sampaio, G. Meco, E. Barbosa, A. M. Bertoli-Avella, G. J. Breedveld, B. A. Oostra, G. Pezzoli & V. Bonifati: The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet, 42, e65 (2005))
5. Kay, D. M., C. P. Zabetian, S. A. Factor, J. G. Nutt, A. Samii, A. Griffith, T. D. Bird, P. Kramer, D. S. Higgins & H. Payami: Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord, 21, 519-23 (2006))
6. Khan, N. L., S. Jain, J. M. Lynch, N. Pavese, P. Abou-Sleiman, J. L. Holton, D. G. Healy, W. P. Gilks, M. G. Sweeney, M. Ganguly, V. Gibbons, S. Gandhi, J. Vaughan, L. H. Eunson, R. Katzenschlager, J. Gayton, G. Lennox, T. Revesz, D. Nicholl, K. P. Bhatia, N. Quinn, D. Brooks, A. J. Lees, M. B. Davis, P. Piccini, A. B. Singleton & N. W. Wood: Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain, 128, 2786-96 (2005)) (Pubitemid 41746633)
7. Goldwurm, S., M. Zini, A. Di Fonzo, D. De Gaspari, C. Siri, E. J. Simons, M. van Doeselaar, S. Tesei, A. Antonini, M. Canesi, A. Zecchinelli, C. Mariani, N. Meucci, G. Sacilotto, R. Cilia, I. U. Isaias, A. Bonetti, F. Sironi, S. Ricca, B. A. Oostra, V. Bonifati & G. Pezzoli: LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord, 12, 410-9 (2006)) (Pubitemid 44430175)
8. Kachergus, J., I. F. Mata, M. Hulihan, J. P. Taylor, S. Lincoln, J. Aasly, J. M. Gibson, O. A. Ross, T. Lynch, J. Wiley, H. Payami, J. Nutt, D. M. Maraganore, K. Czyzewski, M. Styczynska, Z. K. Wszolek, M. J. Farrer & M. Toft: Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet, 76, 672-80 (2005)) (Pubitemid 40432174)
9. Giasson, B. I., J. P. Covy, N. M. Bonini, H. I. Hurtig, M. J. Farrer, J. Q. Trojanowski & V. M. Van Deerlin: Biochemical and pathological characterization of Lrrk2. Ann Neurol, 59, 315-22 (2006)) (Pubitemid 43202485)
10. Infante, J., E. Rodriguez, O. Combarros, I. Mateo, A. Fontalba, J. Pascual, A. Oterino, J. M. Polo, C. Leno & J. Berciano: LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. Neurosci Lett, 395, 224-6 (2006)) (Pubitemid 43213149)
11. West, A. B., D. J. Moore, S. Biskup, A. Bugayenko, W. W. Smith, C. A. Ross, V. L. Dawson & T. M. Dawson: Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A, 102, 16842-7 (2005))
12. Reichling, L. J. & S. M. Riddle: Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity. Biochem Biophys Res Commun, 384, 255-8 (2009))
13. Luzon-Toro, B., E. Rubio de la Torre, A. Delgado, J. Perez-Tur & S. Hilfiker: Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum Mol Genet, 16, 2031-9 (2007))
14. Gloeckner, C. J., A. Schumacher, K. Boldt & M. Ueffing: The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem, 109, 959-68 (2009))
15. Liou, A. K., R. K. Leak, L. Li & M. J. Zigmond: Wild-type LRRK2 but not its mutant attenuates stressinduced cell death via ERK pathway. Neurobiol Dis, 32, 116-24 (2008))
16. White, L. R., M. Toft, S. N. Kvam, M. J. Farrer & J. O. Aasly: MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. J Neurosci Res, 85, 1288-94 (2007)) (Pubitemid 46724372)
17. Stetler, R. A., G. Cao, Y. Gao, F. Zhang, S. Wang, Z. Weng, P. Vosler, L. Zhang, A. Signore, S. H. Graham & J. Chen: Hsp27 protects against ischemic brain injury via attenuation of a novel stress-response cascade upstream of mitochondrial cell death signaling. J Neurosci, 28, 13038-55 (2008))
18. Herman, J. G., J. R. Graff, S. Myohanen, B. D. Nelkin & S. B. Baylin: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A, 93, 9821-6 (1996))
19. King-Batoon, A., J. M. Leszczynska & C. B. Klein: Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ Mol Mutagen, 49, 36-45 (2008)) (Pubitemid 351293011)
20. Anand, V. S. & S. P. Braithwaite: LRRK2 in Parkinson's disease: biochemical functions. FEBS J, 276, 6428-35 (2009))
21. Heo, H. Y., J. M. Park, C. H. Kim, B. S. Han, K. S. Kim & W. Seol: LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp Cell Res, 316, 649-56 (2010))
22. Dang, D. T., F. Chen, M. Kohli, C. Rago, J. M. Cummins & L. H. Dang: Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res, 65, 9485-94 (2005)) (Pubitemid 41508018)
23. Gate, L., R. S. Majumdar, A. Lunk & K. D. Tew: Influence of glutathione S-transferase pi and p53 expression on tumor frequency and spectrum in mice. Int J Cancer, 113, 29-35 (2005)) (Pubitemid 39507307)
24. Ritchie, K. J., C. J. Henderson, X. J. Wang, O. Vassieva, D. Carrie, P. B. Farmer, M. Gaskell, K. Park & C. R. Wolf: Glutathione transferase pi plays a critical role in the development of lung carcinogenesis following exposure to tobacco-related carcinogens and urethane. Cancer Res, 67, 9248-57 (2007)) (Pubitemid 47535913)
25. Gonzalez-Gomez, P., M. J. Bello, D. Arjona, J. Lomas, M. E. Alonso, J. M. De Campos, J. Vaquero, A. Isla, M. Gutierrez & J. A. Rey: Promoter hypermethylation of multiple genes in astrocytic gliomas. Int J Oncol, 22, 601-8 (2003))
26. Niu, D., J. Zhang, Y. Ren, H. Feng & W. N. Chen: HBx genotype D represses GSTP1 expression and increases the oxidative level and apoptosis in HepG2 cells. Mol Oncol, 3, 67-76 (2009))
27. Yuan, Y., Z. R. Qian, T. Sano, S. L. Asa, S. Yamada, N. Kagawa & E. Kudo: Reduction of GSTP1 expression by DNA methylation correlates with clinicopathological features in pituitary adenomas. Mod Pathol, 21, 856-65 (2008)) (Pubitemid 351896660)
28. Zhang, Y. J., Y. Chen, H. Ahsan, R. M. Lunn, S. Y. Chen, P. H. Lee, C. J. Chen & R. M. Santella: Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. Cancer Lett, 221, 135-43 (2005)) (Pubitemid 40460400)
29. Dourado, D. F., P. A. Fernandes & M. J. Ramos: Mammalian cytosolic glutathione transferases. Curr Protein Pept Sci, 9, 325-37 (2008))
30. Hayes, J. D., J. U. Flanagan & I. R. Jowsey: Glutathione transferases. Annu Rev Pharmacol Toxicol, 45, 51-88 (2005)) (Pubitemid 40261798)
31. Henderson, C. J. & C. R. Wolf: Disruption of the glutathione transferase pi class genes. Methods Enzymol, 401, 116-35 (2005)) (Pubitemid 43052389)
32. Ye, Z. & H. Song: Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis. Eur J Cancer, 41, 980-9 (2005)) (Pubitemid 40602849)
33. Asakura, T., A. Sasagawa, H. Takeuchi, S. Shibata, H. Marushima, S. Mamori & K. Ohkawa: Conformational change in the active center region of GST P1-1, due to binding of a synthetic conjugate of DXR with GSH, enhanced JNK-mediated apoptosis. Apoptosis, 12, 1269-80 (2007)) (Pubitemid 46890383)
34. Hegazy, U. M., K. Tars, U. Hellman & B. Mannervik: Modulating catalytic activity by unnatural amino acid residues in a GSH-binding loop of GST P1-1. J Mol Biol, 376, 811-26 (2008))
35. Kabler, S. L., A. Seidel, J. Jacob, J. Doehmer, C. S. Morrow & A. J. Townsend: Differential protection by human glutathione S-transferase P1 against cytotoxicity of benzo (a)pyrene, dibenzo (a,l)pyrene, or their dihydrodiol metabolites, in bi-transgenic cell lines that co-express rat versus human cytochrome P4501A1. Chem Biol Interact, 179, 240-6 (2009))
36. Golbe, L. I., G. Di Iorio, K. Markopoulou, A. Athanassiadou, S. Papapetropoulos, R. L. Watts, J. M. Vance, V. Bonifati, T. A. Williams, J. R. Spychala, E. S. Stenroos & W. G. Johnson: Glutathione S-transferase polymorphisms and onset age in alpha-synuclein A53T mutant Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet, 144B, 254-8 (2007)) (Pubitemid 46606653)
37. Smeyne, M., J. Boyd, K. Raviie Shepherd, Y. Jiao, B. B. Pond, M. Hatler, R. Wolf, C. Henderson & R. J. Smeyne: GSTpi expression mediates dopaminergic neuron sensitivity in experimental parkinsonism. Proc Natl Acad Sci U S A, 104, 1977-82 (2007)) (Pubitemid 46239889)
38. Wang, T., P. Arifoglu, Z. Ronai & K. D. Tew: Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun Nterminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem, 276, 20999-1003 (2001))